Lei Wang, Mingzhe Yan, Reyisaimu Wumaierjiang, Qiqi Zhang, Jie Xiang, Yong Feng, Rui Li
{"title":"HIV感染者转换抗逆转录病毒治疗方案的历史与血脂之间的关系:一项回顾性研究。","authors":"Lei Wang, Mingzhe Yan, Reyisaimu Wumaierjiang, Qiqi Zhang, Jie Xiang, Yong Feng, Rui Li","doi":"10.1089/aid.2024.0079","DOIUrl":null,"url":null,"abstract":"<p><p>It remains unclear whether the history of switching antiretroviral therapy (ART) regimens is a standalone risk factor for lipid deterioration in people living with HIV (PLWH). This study aims to explore the relationship between ART regimen switching history and lipid profiles in PLWH. This is a retrospective analysis of data from HIV-positive individuals aged 16-82, enrolled at Jinyintan Hospital in Wuhan, China, between January 2018 and June 2022. We investigated the potential link between their history of switching ART regimens and their lipid profiles. Locally weighted scatter plot smoother (LOESS) curves were used to depict the dynamic changes in lipid profiles over time. Linear mixed-effects models were employed to assess the differences in lipid levels between individuals with and without a history of ART switches. Out of 708 patients with HIV who began ART between January 2018 and June 2022, 207 (29%) switched regimens at least once, while 501 (71%) remained on their initial regimen throughout the study. Individuals with a history of switching ART exhibited less favorable lipid profiles as identified by LOESS analysis. Linear mixed-effects models indicate that participants who had not previously altered their ART regimens displayed notably lower levels of total cholesterol to high-density lipoprotein (HDL) ratio, total cholesterol, and triglycerides compared to those with a history of ART regimen changes (total cholesterol to HDL ratio, difference -0.19, 95% CI: -0.34 to -0.04; total cholesterol, difference -0.13, 95% CI: -0.25 to 0.00; triglycerides, difference -0.27, 95% CI: -0.43 to -0.11). In contrast, individuals with a history of ART regimen switching had noticeably lower HDL cholesterol (HDL-C) levels [difference: 0.04; 95% confidence intervals (CI) 0.00 to 0.07]. This means that the history of switching ART regimens may be associated with lipid deterioration in PLWH.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Association Between the History of Switching Antiretroviral Therapy Regimens and Lipid Profile in People Living with HIV: A Retrospective Study.\",\"authors\":\"Lei Wang, Mingzhe Yan, Reyisaimu Wumaierjiang, Qiqi Zhang, Jie Xiang, Yong Feng, Rui Li\",\"doi\":\"10.1089/aid.2024.0079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>It remains unclear whether the history of switching antiretroviral therapy (ART) regimens is a standalone risk factor for lipid deterioration in people living with HIV (PLWH). This study aims to explore the relationship between ART regimen switching history and lipid profiles in PLWH. This is a retrospective analysis of data from HIV-positive individuals aged 16-82, enrolled at Jinyintan Hospital in Wuhan, China, between January 2018 and June 2022. We investigated the potential link between their history of switching ART regimens and their lipid profiles. Locally weighted scatter plot smoother (LOESS) curves were used to depict the dynamic changes in lipid profiles over time. Linear mixed-effects models were employed to assess the differences in lipid levels between individuals with and without a history of ART switches. Out of 708 patients with HIV who began ART between January 2018 and June 2022, 207 (29%) switched regimens at least once, while 501 (71%) remained on their initial regimen throughout the study. Individuals with a history of switching ART exhibited less favorable lipid profiles as identified by LOESS analysis. Linear mixed-effects models indicate that participants who had not previously altered their ART regimens displayed notably lower levels of total cholesterol to high-density lipoprotein (HDL) ratio, total cholesterol, and triglycerides compared to those with a history of ART regimen changes (total cholesterol to HDL ratio, difference -0.19, 95% CI: -0.34 to -0.04; total cholesterol, difference -0.13, 95% CI: -0.25 to 0.00; triglycerides, difference -0.27, 95% CI: -0.43 to -0.11). In contrast, individuals with a history of ART regimen switching had noticeably lower HDL cholesterol (HDL-C) levels [difference: 0.04; 95% confidence intervals (CI) 0.00 to 0.07]. This means that the history of switching ART regimens may be associated with lipid deterioration in PLWH.</p>\",\"PeriodicalId\":7544,\"journal\":{\"name\":\"AIDS research and human retroviruses\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS research and human retroviruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/aid.2024.0079\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS research and human retroviruses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/aid.2024.0079","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
The Association Between the History of Switching Antiretroviral Therapy Regimens and Lipid Profile in People Living with HIV: A Retrospective Study.
It remains unclear whether the history of switching antiretroviral therapy (ART) regimens is a standalone risk factor for lipid deterioration in people living with HIV (PLWH). This study aims to explore the relationship between ART regimen switching history and lipid profiles in PLWH. This is a retrospective analysis of data from HIV-positive individuals aged 16-82, enrolled at Jinyintan Hospital in Wuhan, China, between January 2018 and June 2022. We investigated the potential link between their history of switching ART regimens and their lipid profiles. Locally weighted scatter plot smoother (LOESS) curves were used to depict the dynamic changes in lipid profiles over time. Linear mixed-effects models were employed to assess the differences in lipid levels between individuals with and without a history of ART switches. Out of 708 patients with HIV who began ART between January 2018 and June 2022, 207 (29%) switched regimens at least once, while 501 (71%) remained on their initial regimen throughout the study. Individuals with a history of switching ART exhibited less favorable lipid profiles as identified by LOESS analysis. Linear mixed-effects models indicate that participants who had not previously altered their ART regimens displayed notably lower levels of total cholesterol to high-density lipoprotein (HDL) ratio, total cholesterol, and triglycerides compared to those with a history of ART regimen changes (total cholesterol to HDL ratio, difference -0.19, 95% CI: -0.34 to -0.04; total cholesterol, difference -0.13, 95% CI: -0.25 to 0.00; triglycerides, difference -0.27, 95% CI: -0.43 to -0.11). In contrast, individuals with a history of ART regimen switching had noticeably lower HDL cholesterol (HDL-C) levels [difference: 0.04; 95% confidence intervals (CI) 0.00 to 0.07]. This means that the history of switching ART regimens may be associated with lipid deterioration in PLWH.
期刊介绍:
AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes.
AIDS Research and Human Retroviruses coverage includes:
HIV cure research
HIV prevention science
- Vaccine research
- Systemic and Topical PreP
Molecular and cell biology of HIV and SIV
Developments in HIV pathogenesis and comorbidities
Molecular biology, immunology, and epidemiology of HTLV
Pharmacology of HIV therapy
Social and behavioral science
Rapid publication of emerging sequence information.